17:35 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture studies suggest inhibition of...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
19:38 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

Bremelanotide: Ph III data

Top-line data from a total of 1,202 premenopausal women with HSDD in the modified intent-to-treat (mITT) populations of the identical, 24-week, double-blind, U.S. and Canadian Phase III Reconnect Studies 301 and 302 showed that 1.75...
07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into...
07:00 , Oct 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Wilms tumor 1 (WT1); CD3e molecule epsilon (CD3-TCR complex)(CD3ε; CD3E)

Cancer INDICATION: Cancer; leukemia Cell culture and mouse studies suggest a bispecific T cell engager (BiTE) antibody targeting WT1 and CD3ε could help treat cancer and leukemia. The BiTE consisted of ESK1 - which is...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Bremelanotide: Phase III started

Palatin began the 32-week, double-blind, placebo-controlled, North American Phase III reconnect study to evaluate subcutaneous bremelanotide self-administered as needed in about 550 premenopausal women with hypoactive sexual desire disorder (HSDD) -- a subtype of FSD....
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Tefina: Phase II data

The double-blind, international Phase II AMB-2012-01 trial in 253 pre- and post-menopausal women experiencing acquired female orgasmic disorder showed that 0.6 mg Tefina as needed for 84 days met the primary endpoint of improving the...
08:00 , Feb 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis a-l-iduronidase (IDUA) In vitro and mouse studies suggest megakaryocyte-targeted gene therapy could help treat mucopolysaccharidosis I (MPS I; Hurler syndrome). In a human...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Genetic Alliance other news

Genetic Alliance issued a request for proposals to offer its crowd-sourced Platform for Engaging Everyone Responsibly (PEER). Genetic Alliance will offer a customized, organization-branded installation of PEER to up to nine disease and/or condition advocacy...
07:00 , Mar 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia; solid tumors Human leukocyte antigen (HLA); Wilms tumor 1 (WT1) Mouse and cell culture studies suggest a human mAb targeting the WT1-HLA complex could...